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Abstract
Significance: Synaptic degeneration, an early pathological feature in Alzheimer’s disease (AD), is closely corre-
lated to impaired cognitive function and memory loss. Recent studies suggest that involvement of amyloid-beta
peptide (Ab) in synaptic mitochondrial alteration underlies these synaptic lesions. Thus, to understand the Ab-
associated synaptic mitochondrial perturbations would fortify our understanding of synaptic stress in the path-
ogenesis of AD. Recent Advances: Increasing evidence suggests that synaptic mitochondrial dysfunction is
strongly associated with synaptic failure in many neurodegenerative diseases including AD. Based on recent
findings in human AD subjects, AD animal models, and AD cellular models, synaptic mitochondria undergo
multiple malfunctions including Ab accumulation, increased oxidative stress, decreased respiration, and com-
promised calcium handling capacity, all of which occur earlier than changes seen in nonsynaptic mitochondria
before predominant AD pathology. Of note, the impact of Ab on mitochondrial motility and dynamics exacerbates
synaptic mitochondrial alterations. Critical Issues: Synaptic mitochondria demonstrate early deficits in AD; in
combination with the role that synaptic mitochondria play in sustaining synaptic functions, deficits in synaptic
mitochondria may be a key factor involved in an early synaptic pathology in AD. Future Directions: The im-
portance of synaptic mitochondria in supporting synapses and the high vulnerability of synaptic mitochondria to
Ab make them a promising target of new therapeutic strategy for AD. Antioxid. Redox Signal. 16, 1467–1475.
Introduction
Neurons are distinct from many other eukaryotic cells bythe unique architecture of the long processes stemming
from the cell body. Synapses are the neuronal contact sites
through which neurons receive and send information from/to
each other (1, 16). Energy provision and calcium fluctuation in
synapses are the prerequisite of inter-neuronal communica-
tion (73); to meet the high energy demands and to cope
with constant calcium flux, mitochondria are enriched in
synapses for on-site energy provision and calcium modula-
tion (20, 55, 81). It follows then that deficits in mitochondrial
function and amyloid-beta peptide (Ab) accumulation in
synapses lead to reduced synaptic activity and consequent
neuronal perturbations. Such concurrent synaptic alteration
and mitochondrial dysfunction have been observed in
many neurodegenerative diseases including the Alzheimer’s
disease (AD).
AD characterized by progressive memory loss and cogni-
tive impairment is the most common type of dementia in aged
people. The cognitive impairments of patients with AD are
strongly associated with synaptic deficits and synaptic loss
(36, 84, 89). Studies of synaptic properties have shown that
synaptic damage is an early event in the pathogenesis of AD
and worsens with disease progression (44, 89). Although the
precise etiology of synaptic failure in AD has not yet been
elucidated, Ab is considered to be an underlying pathogenic
factor. Although the list of detrimental impact of Ab accu-
mulation on synapses/synaptic function is ever expanding,
recent studies point to mitochondrial dysfunction as a major
player in the synaptic alterations seen in AD (25). Notably,
recent efforts to identify the changes in synaptic mitochondria
in an Ab-rich environment are significantly advancing our
understanding of the mechanisms of synaptic degeneration in
AD, especially in early stages before the presence of Ab sets in
motion the devastating cognitive impairments. In this article,
we will focus on the subgroup of synaptic mitochondria and
summarize the progress to date in research on synaptic mi-
tochondrial alterations in AD.
Mitochondria at Synapses
Mitochondria are the energy warehouse of eukaryotic cells.
In addition to their bioenergetics trait, mitochondria play a
crucial role in maintenance of intracellular calcium homeo-
stasis and induction of apoptosis, thus meaning that mito-
chondria are essential organelles in cell survival. Increasing
evidence suggests that mitochondria in different types of cells
1Higuchi Bioscience Center and 2Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, Lawrence,
Kansas.
ANTIOXIDANTS & REDOX SIGNALING
Volume 16, Number 12, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2011.4277
1467
and even in different subcompartments of one cell differ sig-
nificantly in their function, morphology, and other properties;
accordingly, mitochondria within one cell can be divided into
multiple subgroups (43, 83). This recognition of mitochondrial
heterogeneity facilitates our understanding of mitochondrial
biology and even more so of mitochondrial pathology in
many pathological scenarios.
A typical pattern of mitochondrial heterogeneity is seen in
neurons. According to their physical position, neuronal mi-
tochondria are categorized into synaptic mitochondria and
nonsynaptic mitochondria (19, 25, 82). Although they share
the same origin, synaptic mitochondria present in various
sizes, trafficking patterns, function, lifespan, and other prop-
erties compared with their relatives residing in neuronal soma
(4, 12, 46). Synaptic mitochondria are defined as those docked
and aggregated in synapses; they play an important role in
maintaining normal synaptic function through their ability to
meet the high-energy demand of synapses while maintaining
synaptic calcium. It is generally accepted that synaptic mito-
chondria are long lived but are more vulnerable to cumulative
damage than nonsynaptic mitochondria (4). Several labora-
tories including ours have shown that synaptic mitochondria
undergo increased oxidation during aging (2, 25, 54). In ad-
dition, synaptic mitochondria have higher levels of cyclo-
philin D (CypD), thus rendering them more susceptible to
calcium insult (4, 25, 60). Our recent study demonstrated that
synaptic mitochondria had higher levels of Ab accumulation
significantly before such accumulation in nonsynaptic mito-
chondria in a transgenic AD mouse model overexpressing Ab
(25). Thus, improved understanding of synaptic mitochon-
drial biology and pathology mechanisms is especially im-
portant as we attempt to further elucidate the etiology of
synaptic degeneration in pathological scenarios such as aging
and AD.
Synaptic mitochondria and synaptic neurotransmission
Neurons form a network to exchange information. The
propagation of information is achieved by synaptic trans-
mission, which entails presynaptic neurotransmitter release
to synaptic cleft to stimulate postsynaptic neurons. ATP is
essential to many steps of synaptic transmission such as the
tethering, uncoating, and refilling of synaptic vesicles (50, 59,
81). It has been proposed that ATP per se is a neurotrans-
mitter for the fast synaptic transmission (6). Although the
glycolysis process contributes a modest level of ATP, neu-
rons normally derive ATP from aerobic respiration via
mitochondrial oxidative phosphorylation (5). However, in
many pathological scenarios such as ischemia, deprivation
of mitochondrial respiration leads to decreased ATP pro-
duction and compromised synaptic transmission (18, 68).
Further, the administration of glucose to enhance ATP pro-
duction can efficiently attenuate protonophore-instigated
synaptic depression (9, 61). These findings suggest the
importance of mitochondrial ATP in supporting normal
synaptic transmission.
Calcium is another essential player in neurotransmission
and is also involved in neuronal plasticity. Synaptic mem-
brane potential depolarization induces activation of voltage-
dependent calcium channels, which consequently stimulates
calcium entry into presynapses with rapidly increased cal-
cium levels at intra and presynapse sites (38, 40). The rise in
calcium levels is the initiating step for synaptic vesicle trans-
port and membrane fusion release as well as for reuptake of
neurotransmitters (15, 32, 47, 76); such transient increases in
synaptic calcium levels are subsequently quenched to avoid
injury due to long-lasting calcium stimulation (17, 20). Pre-
vailing opinion supports the notion that mitochondria play a
central role in regulating calcium ions in synapses after cal-
cium influx (3, 66, 67). Although mitochondria and endo-
plasmic reticulum (ER) are major cellular structures with
calcium buffering capacity, it has been shown that synaptic
mitochondria have more rapid calcium uptake than ER and
that mitochondria more quickly release calcium to sustain
prolonged neurotransmitter exocytosis (64, 66, 67). The com-
munication between ER and mitochondria is probably a part
of an important mechanism for regulation of intra-synaptic
calcium (56, 64). Therefore, synaptic transmission relies lar-
gely on mitochondria accumulation in synapses and mito-
chondrial ability to modulate calcium levels. The density of
synaptic mitochondria and their role in energy provision and
calcium modulation are key factors working to support syn-
aptic transmissions. Deficits in synaptic mitochondria com-
promise synaptic activity.
Synaptic mitochondrial generation and trafficking
Mitochondria are membrane-bound mobile organelles that
undergo constant movement in neurons and accumulate in
synapses to meet synaptic energy demands. Although there
are several copies of DNA in mitochondrion, mitochondrial
DNA only encodes 13 essential mitochondrial proteins (less
than 5% of all mitochondrial proteins). In fact, most essential
mitochondrial proteins are encoded by nucleic DNA and then
imported into mitochondria. Mitochondrial synthesizing and
packaging machineries are located in the perinuclear region of
neuronal cytoplasm and are extremely deficient in dendrites
and axons (13, 39). Therefore, mitochondria are generated in
neuronal soma and transported to synapses via mitochondrial
transport systems to achieve their synaptic support function.
Based on studies to date, kinesin is responsible for mito-
chondrial anterograde transport that carries mitochondria
from soma to the distal axon tip (35, 63); and dynein is im-
portant for mitochondrial retrograde transport that inversely
sends mitochondria toward the proximate axon end (63).
Adaptor proteins play an important role in binding mito-
chondria to motor proteins (kinesin and dynein). A variety of
adaptor proteins have been identified to connect mitochon-
dria to kinesin, that is, Miro (70), Milton (57) and syntabulin
(77). These adaptor proteins play a dual role in mitochondrial
trafficking—they tie mitochondria to kinesin, thus enabling
mitochondrial transport from soma to synapses; on the other
side, these adaptor proteins dissociate from kinesin to enable
mitochondrial docking around synapses. For example, Miro,
a calcium sensor protein, recognizes a high level of calcium
and then discharges mitochondria from kinesin (7, 48). Mi-
tochondrial transport is also regulated by multiple intracel-
lular signaling pathways such as protein kinase A (PKA) (69),
glycogen synthase kinase 3b (GSK 3b) (21, 69), and mitogen-
activated protein kinase (MAPK) (75) that control mitochon-
drial undocking from motor proteins. The finely controlled
mitochondrial trafficking and docking processes enable mi-
tochondria to be physically adjacent to synapses to modulate
synaptic function.
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Alterations of Synaptic Mitochondria in AD
Mitochondrial dysfunction is recognized as a predominant
AD pathological change that occurs concurrently with syn-
aptic alterations and exacerbates disease progression. Based
on the critical role of synaptic mitochondria in sustaining
synaptic activity, recent efforts have focused on unraveling
the mechanisms driving synaptic mitochondrial dysfunction
as a potential player in synaptic failure in AD.
Deficits in synaptic mitochondrial function in AD
Investigations into the pathogenesis of AD in the past
century have yielded a large body of evidence showing that
Ab and Ab-associated cellular changes are important causa-
tive factors underlying neuronal perturbation and synaptic
distress in AD. Ab is a small molecule cleaved from amyloid-
beta precursor protein (APP) by the proteolysis of b- and c-
secretases. Ab plaques and intra-cellular, particularly intra-
mitochondrial Ab, are pathological features in AD. Notably,
recent studies revealed that Ab accumulates inside AD brain
mitochondria including synaptic mitochondria (Fig. 1) (11,
22–26, 30, 37, 49, 51, 62, 79, 80, 92, 93) and that the levels of
mitochondrial Ab are associated with abnormalities of mito-
chondrial structure and function. Indeed, mitochondrial
malfunction has been documented in the studies on human
AD and AD animal models as well as Ab-overexpressing cell
models, thus suggesting that deficits in mitochondrial func-
tion occur in an Ab-rich environment. The most recognized
forms of mitochondrial dysfunction in AD include Ab accu-
mulation in brain mitochondria, decreased mitochondrial
ATP provision, elevated mitochondria-associated oxidative
stress, increased mitochondrial permeability transition, re-
duced mitochondrial calcium modulating capacity, impaired
respiratory function, and release of pro-apoptogenic factors
from mitochondria (10, 24–26, 42, 49, 62, 65, 71, 79, 80, 92).
Synaptic mitochondria are an early target of Ab, thus dem-
onstrating early pathological changes before observed global
brain mitochondrial damage.
Synaptosomes are membrane-sealed neuronal terminals
containing synaptic mitochondria and other synapse-related
structures such as synaptic vesicles and lysosomes (29, 72).
In a Mungarro-Menchaca et al. study, incubation of synap-
tosomes from Wistar rats with Ab25–35 (58) altered
ultrastructure of synaptosomes with swollen synaptic mito-
chondria and significantly reduced the number of synaptic
vesicles. The combination of Ab with Ryanodine, an agonist of
Ryanodine receptor, exacerbated the aforementioned ultra-
structural changes of synaptic mitochondria and synaptic
vesicles, thus suggesting that Ab toxicity is more predominant
in calcium-stressed synaptosomes (58). Additionally, an
independent in vitro experiment using Ab1–40 to treat syn-
aptosomes isolated from C57B mice demonstrated remark-
able synaptic mitochondrial changes, including membrane
potential collapse, mitochondrial calcium accumulation, and
increased free radical production (41); these studies raise the
possibility of the potential impact of Ab on synaptic activity
and synaptic mitochondrial properties. Lastly, an in vivo
study in human patients with AD and an AD mouse model
(Tg2576 mice) provided direct evidence of the existence of Ab
and Tau pathology in synaptosomes (33, 34).
Since synaptic mitochondria are more vulnerable to cu-
mulative damage induced by deleterious factors such as Ab,
it is possible that synaptic mitochondria undergo earlier chan-
ges than detectable alterations in global brain mitochondria.
An AD mouse model (Tg mAPP mice) demonstrates age-
dependent brain Ab accumulation starting in 4–5-month-old
mice and exacerbating with age, thus mimicking the process
of Ab pathology in human AD (25). Tg mAPP synaptic mi-
tochondria from young mice in which no brain Ab plaques
FIG. 1. Accumulation of Ab in synaptic mitochondria.
Immunogold electron microscopy images with a specific
Ab1–42 antibody followed by gold-conjugated antibody
(18 nm) to show the presence of intra-mitochondrial Ab ac-
cumulation (white arrow) in 12-month-old Tg mAPP. The
black arrow denotes mitochondria. The asterisk (*) denotes a
synapse. M indicated mitochondria. Ab, amyloid-beta pep-
tide; APP, amyloid-beta precursor protein.
FIG. 2. Synaptic mitochondria are more vulnerable to Ab
accumulation. Synaptic mitochondria and nonsynaptic mi-
tochondria were prepared from Tg mAPP mice at age of 4
months and subjected to measure the levels of Ab1–40 and
Ab1–42. The data showed that levels of both Ab species were
significantly increased in synaptic mitochondria.
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were found showed significant accumulation of Ab; in con-
trast, the Ab levels in the same preparations of Tg mAPP
nonsynaptic mitochondria were significantly lower (Fig. 2).
Both Tg mAPP mouse synaptic and nonsynaptic mitochon-
dria demonstrated elevated Ab levels with age, but Tg mAPP
synaptic mitochondria had a more prominent increase in Ab
levels than nonsynaptic mitochondria in Tg mAPP mice at the
same age. These results provide evidence that synaptic mi-
tochondria are more vulnerable to Ab accumulation than
nonsynaptic mitochondria and that synaptic mitochondrial
Ab aggregation is an early mitochondrial pathological process
relevant to the Ab pathology.
As a result, Ab-insulted synaptic mitochondria from young
Tg mAPP mice undergo significant decline in respiratory
function and cytochrome c oxidase activity, increased oxida-
tive stress, and enhanced probability of mitochondrial per-
meability transition pore processes (25). Further, Ab-insulted
synaptic mitochondria also showed increased expression of
CypD and Ab-binding alcohol dehydrogenase (ABAD). Both
mitochondrial proteins (CypD and ABAD) have been shown
to interact with Ab, thereby accelerating and exacerbating
mitochondrial stress in an Ab-rich environment (24, 26, 27, 49,
60, 80, 91). In contrast, nonsynaptic mitochondria isolated
from young Tg mAPP mice demonstrated preserved function
comparable to those in age-matched wild type mice. How-
ever, both synaptic and nonsynaptic mitochondria from aged
Tg mAPP mice presented compromised function, but changes
in synaptic mitochondria were more profound. These find-
ings suggest that synaptic mitochondria are an early victim of
Ab and undergo pathological changes before nonsynaptic
mitochondria. Consistent with our observation, Gillardon’s
study reported detectable Ab accumulation in synaptosomal
fractions from young Tg2576 mice (another AD mouse model)
before detectable brain Ab plaques; accordingly, synaptic
mitochondria were functionally compromised in these young
Tg2576 mice (34). Taken together, these data indicate that
synaptic mitochondrial functional disturbances are early
deficits in the progress of AD and synaptic mitochondrial
dysfunction is a key player in Ab-mediated mitochondrial
and neuronal toxicity.
Synaptic mitochondrial transport
and dynamics change in AD
Mitochondria are mobile and dynamic organelles. The
accumulation of mitochondria in synapses depends on mito-
chondrial transport to neuronal terminals. The constant
mitochondrial fusion and fission regulates mitochondrial
density and morphology and is closely related to mitochon-
drial function. Indeed, concomitant mitochondrial dysfunc-
tion and motility change has been observed in patients with
AD and Ab overexpression cell lines as well as in AD animal
models. As a major causative factor of AD, Ab disrupts mi-
tochondrial motility and dynamics in neurites, thus resulting
in disorganized synaptic mitochondrial distribution. Rui et al.
showed that acute treatment with 20 lM Ab25–35 on cultured
cortical neurons caused a significant decrease in neuronal
mitochondrial movement (69). Several other laboratories have
obtained similar results regarding the impact of Ab on neu-
ritic mitochondrial movement including axonal mitochon-
drial transport (8, 21, 25, 85). Two recent studies using chronic
treatment of low concentration, for example, 200 nM, oligo-
meric Ab on neurons, which mimics the Ab toxicity in
AD brains, reported significant alterations in axonal mito-
chondrial transport (21, 25). Impairment on anterograde
movement of Ab–superimposed axonal mitochondria is more
pronounced than on retrograde movement (8, 25) as shown
by decreased percentage of anterograde mitochondria and
reduced mobility of anterograde speed. In contrast, the ret-
rograde speed is not significantly decreased after treatment
with 200 nM oligomeric Ab for 24 h (Fig. 3) (25). The precise
mechanism of this discrepancy in impairment on mitochon-
drial anterograde and retrograde movement remains un-
known. Given that PKA and GSK 3b signaling cascades are
implicated in Ab-induced mitochondrial trafficking impair-
ments (21, 69) and that activation of PKA or suppression of
GSK 3b rescues Ab-injured mitochondrial motility (21, 69),
interference with the mitochondria-dependent signal trans-
duction pathway might be a key factor involved in synaptic
mitochondrial transport and trafficking such as Ab-mediated
injury.
In addition to changes in mitochondrial movement, Ab also
is an instigating factor in abnormal mitochondrial dynamics,
thus leading to defects in mitochondrial fusion and fission. A
series of studies from the Zhu’s laboratory demonstrated the
altered expression levels of mitochondrial fusion- and fission-
related proteins that are thought to be associated with in-
creased mitochondrial fission and lowered mitochondrial
fusion in an Ab-rich environment (86–88). This imbalance in
mitochondrial dynamics resulted in increased mitochondrial
fragmentation, decreased neuritic mitochondrial density, and
altered synaptic mitochondrial distribution. Similar changes
have been further observed in patients with AD, APP over-
expressing cell lines, and Ab-treated primary cultured neu-
rons in several studies (8, 25, 52, 87, 88) including ours (Fig. 4).
Among many changes in mitochondrial fusion and fission
proteins in AD, dynamin-like protein 1 (Dlp1) has been in-
tensively studied—reports showed changes in Dlp1 expres-
sion levels (87), increased Drp1 S-nitrosylation (14), and Drp1
interaction with Ab (52), thus implicating the role of Dlp1 in
neuronal mitochondrial dynamics changes seen in AD.
Changes in Ab-related neuronal/synaptic mitochondrial
motility and dynamics are closely related to synaptic mito-
chondrial malfunction as well as consequent impaired synaptic
function. Therefore, although the studies on mitochondrial
FIG. 3. Ab affects axonal mitochondrial movement. Re-
presentative kymograph images of the vehicle and Ab1–42-
treated axonal mitochondrial movement showing injured
axonal mitochondrial movement. The arrows denote the tra-
ces of mitochondrial movement.
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motility and dynamics change in AD are still at an early stage,
elucidation of the detailed mechanisms will be likely to fully
depict the role of synaptic mitochondrial morphological
and transport changes in mitochondrial and neuronal injury
in AD.
Summary and Perspectives
Increasing evidence suggests the close correlation of brain
mitochondrial dysfunction with synaptic degeneration, both
of which are early lesions in AD. Here, we focused on changes
in synaptic mitochondria in AD, particularly on the exposure
to Ab and summarized recent progress in the study of
Ab-related synaptic mitochondrial pathology. Due to their
physical proximity to synapses, synaptic mitochondria dem-
onstrate a critical role in directly supporting synaptic activity;
in addition, synaptic mitochondria undergo constant activa-
tion to meet energy demands and control calcium modulation
in synapses. Correspondingly, in comparison to somatic
mitochondria, synaptic mitochondria are more vulnerable to
cumulative damages due to Ab insult (4, 25, 60). Synaptic mi-
tochondria demonstrate early Ab accumulation, impaired res-
piration, lowered calcium handling capacity, and enhanced
oxidative stress (25). Importantly, synaptic mitochondria un-
dergo pathological changes before nonsynaptic mitochondria
in presymptomatic AD animal models even in conditions of
FIG. 4. Ab alters axonal mitochondrial distribution. The
axonal mitochondrial density is decreased after Ab1–42
(200 nM) treatment for 24 h on cultured hippocampal neurons
(Lower panel). *p < 0.05 vs. cells treated with vehicle or reversed
Ab42-1. The upper panel shows representative images for
vehicle- or Ab-treated axonal mitochondrial distribution.
Double immunostaining with Mitotracker (red, mitochondrial
marker) and Tau (green, axonal marker) was performed. (To
see this illustration in color the reader is referred to the web
version of this article at www.liebertonline.com/ars).
FIG. 5. Schematic figure to show the role of synaptic mi-
tochondria in supporting synaptic activity. Synaptic mito-
chondria are generated in neuronal soma and further
transported to synapses. Normal synaptic mitochondrial
movement, docking, and dynamics are crucial features for
mitochondria to exert their function on ATP production, cal-
cium modulation, and regulation of cell signaling cascades,
consequently maintaining synaptic plasticity and transmission.
(To see this illustration in color the reader is referred to the web
version of this article at www.liebertonline.com/ars).
FIG. 6. Working hypothesis. In the presence of Ab, mito-
chondrial transport and dynamics are injured with compro-
mised synaptic mitochondrial structure and function, thus
leading to decreased energy metabolism, dysregulated calcium
homeostasis, and perturbed cell signaling cascades, eventually
leading to synaptic injury and cognitive dysfunction.
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low or undetectable levels of Ab in nonsynaptic mitochondria.
In scenarios with substantial Ab pathology, synaptic mito-
chondrial injury is still more predominant than nonsynaptic
mitochondrial damage. Moreover, the negative effect of Ab on
synaptic mitochondrial motility and dynamics significantly and
adversely impacts normal synaptic distribution, density, and
morphology, which, in turn, substantially compromises effects
of synaptic mitochondria on synaptic function (Figs. 5 and 6).
Thus, although alterations of synaptic mitochondria in AD are a
nascent target of AD pathogenesis, the resultant early deficits
and high vulnerability of synaptic mitochondria in response to
Ab toxicity have attracted intensive research efforts. A more
complete understanding of synaptic mitochondrial dysfunction
in AD will also broaden our knowledge regarding the patho-
genesis of this neurodegenerative disease. Current study in this
field is just beginning, and more detailed mechanisms of syn-
aptic mitochondrial pathology in AD should be elucidated to
address the following questions: (i) what are the reasons/
mechanisms of early Ab deposition in synaptic mitochondria; (ii)
what are the precise mechanisms controlling synaptic mito-
chondrial motility and dynamics in ‘‘normal’’ and Ab-related
scenarios; and (iii) what is the impact of early synaptic mito-
chondrial dysfunction on synapses. We believe that the answers
to these questions will provide new insights into synaptic mi-
tochondrial structure/properties relevant to AD pathogenesis
and, in particular, Ab-mediated synaptic pathology.
Early changes in synaptic mitochondria before devastating
Ab pathology in AD and the importance of synaptic mito-
chondria for normal synaptic activity make synaptic mito-
chondria a preferential target for the treatment of AD.
Previous studies have provided evidence for the protection of
mitochondrial function in ameliorating synaptic changes and
the consequent cognitive impairments in AD animal models.
A representative example of the many mitochondria-pro-
tecting approaches is the application of antioxidants to human
AD, AD animal and cell models, which demonstrates signif-
icant amelioration of mitochondrial/neuronal dysfunction
against Ab toxicity (28, 31, 74, 90). More recent studies sug-
gested the striking efficacy of mitochondria-targeting anti-
oxidants including MitoQ, SS peptides, and MitoE in
strengthening mitochondria in their respiration, membrane
potential, and calcium-handling capacity from toxic insults
including the Ab (45, 53, 78). It is noted that MitoQ and SS31
significantly reversed Ab-induced CypD elevation, mito-
chondrial fusion/fission proteins imbalance, and neurite
growth in AD cell models, thus suggesting the close rela-
tionship between neuronal mitochondrial dysfunction and
neuronal/synaptic perturbation and the value of eliminating
neuronal mitochondrial oxidative stress in the treatment of
neuronal/synaptic alterations in AD (53). Thereby, interven-
tions affecting mitochondrial activity are likely promising
therapeutic strategies for halting and treating AD. Rescuing
and protecting synaptic mitochondria in presymptomatic
subjects or in patients suffering from AD with mild cognitive
impairments may be appropriate targets for amelioration of
synaptic alterations at the early stage of AD.
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